Toxicology Report

Science-backed PDE/ADE, OEL & OEB derivation by certified toxicologists with ex-agency experts -

Daptomycin

What is Daptomycin?

CAS No: 103060-53-3

Daptomycin belongs to the antibiotic class and achieves its selective antibacterial effect by inhibiting a bacterial enzyme or structural component essential for pathogen survival and replication while maintaining a defined safety margin against mammalian cell toxicity. The selectivity index between the antibacterially effective concentration and the mammalian cytotoxic concentration defines the therapeutic window. PDE derivation for Daptomycin draws on the critical repeat-dose toxicity study in rodents or higher species, with the NOAEL serving as the point of departure before application of composite uncertainty factors.

The intraspecies uncertainty factor F2 for Daptomycin covers the range of pharmacokinetic and pharmacodynamic variability within the human population, ensuring the derived PDE is protective for sensitive subgroups including paediatric patients with immature CYP450 activity, elderly patients with reduced hepatic and renal clearance, patients with organ impairment affe

To derive PDE/ADE, OEL, and OEB values, Masuu Global follows a scientifically justified, risk-based toxicological assessment approach in accordance with internationally recognized guidelines and industry best practices that are widely accepted by regulatory authorities, including European Medicines Agency (EMA), Pharmaceutical Inspection Co-operation Scheme (PIC/S), and Agência Nacional de Vigilância Sanitária (ANVISA).

Request Your Assessment

Add this compound to your inquiry list and our team will follow up with full documentation, pricing, and licensing terms.

View Inquiry List →
What's included:
Full OEL derivation · ADE/PDE value · Control band assignment · All cited references · EMA / ICH Q9 compliance
9,000+
Toxicological & Exposure
Assessment Reports Delivered
70+
Subject Matter Experts
across global operations
12
In-House Ex-Agency
Toxicologists
3
Certification Bodies:
ERT · UKRT · DABT

Assessment Methodology

Masuu Global follows a scientifically justified, risk-based toxicological approach aligned with internationally recognized guidelines accepted by EMA, PIC/S, and ANVISA.

EMA – Guideline on Setting Health-Based Exposure Limits (HBELs)

Provides the framework for establishing scientifically justified PDE/ADE values for use in shared manufacturing facilities.

PIC/S – Shared Facilities and Contamination Control Guidance

Supports the application of HBEL-based approaches for cross-contamination prevention and cleaning validation.

ICH Q9 – Quality Risk Management

Provides a structured methodology for risk identification, assessment, control, communication, and review.

ICH M7 – Assessment and Control of DNA-Reactive (Mutagenic) Impurities (where applicable)

Applied for compounds with potential mutagenic or genotoxic concerns.

Risk-Based Toxicological Assessment

Comprehensive evaluation of available toxicological and pharmacological data, including NOAEL, LOAEL, BMDL, pharmacological potency, carcinogenicity, reproductive and developmental toxicity, sensitization potential, and target organ toxicity.

Weight-of-Evidence (WoE) Approach

Integration and critical review of all relevant data sources, including non-clinical studies, clinical studies, human exposure data, pharmacological information, post-marketing safety data, and structure–activity relationship (SAR/QSAR) assessments.

Report Preparation Process

Every assessment moves through a rigorous five-stage workflow — from data gathering to regulatory-ready delivery.

01

Comprehensive Data Review

Assessment of pharmacology, toxicology, clinical data, literature, and available regulatory information.

02

Scientific Evaluation

Identification of critical endpoints and selection of appropriate exposure limits.

03

PDE / HBEL Derivation

Transparent and scientifically justified calculations aligned with global toxicological principles.

04

Ex-Agency Expert Review (Our Differentiator)

Reports are reviewed with an ex-agency perspective, bringing regulatory expectations, inspection readiness, and practical implementation into every assessment.

05

Final Report Delivery

Regulatory-ready reports with scientific rationale, calculations, and clear recommendations by certified toxicologists (ERT, UKRT and DABT).

Why Masuu Global?

Our ex-agency toxicologists bring a practical regulatory perspective that transforms how assessments are built, reviewed, and defended.

✓

Regulatory expectation–driven assessments aligned with how authorities actually evaluate submissions.

✓

Inspection-ready reports — scientifically defensible and audit-prepared from day one.

✓

Faster review cycles with direct decision support from certified toxicologists (ERT, UKRT, DABT).

✓

Practical implementation recommendations that translate science into actionable contamination control.

✓

Reduced internal effort — offload complex assessments without sacrificing quality or defensibility.

✓

Global reach across PDE/ADE, HBEL, OEL, OEB, cleaning validation, and impurity assessments.

Ready to request your assessment?

Add this compound to your inquiry list, or browse our full database of 3,000+ molecules.

Frequently Asked Questions

Daptomycin is a cyclic lipopeptide antibiotic produced by Streptomyces roseosporus. It disrupts the cell membrane of Gram-positive bacteria and is given intravenously for complicated skin infections and Staphylococcus aureus bacteremia. Its potential to cause muscle toxicity and eosinophilic pneumonia are relevant considerations in deriving exposure limits.

A PDE or ADE sets a health-based limit on daily exposure to Daptomycin from residual carryover. Manufacturers use it in cross-contamination risk assessments and cleaning validation when the compound is processed in shared equipment or facilities. Whether a report is required depends on how it is used and on applicable regulatory expectations.

A Masuu Global report for Daptomycin presents the scientific rationale, the calculations behind each exposure limit, and clear recommendations for use in risk assessment. Reports are prepared by certified toxicologists and designed to be regulatory-ready, so quality, safety and regulatory teams can follow and review how each value was derived.

A toxicological assessment characterizes the potential health hazards of Daptomycin using the available data. It supports scientifically justified exposure limits, helps manufacturers choose proportionate handling and containment measures, and gives a documented basis for protecting workers and preventing cross-contamination in shared facilities.

Potent pharmacological activity can drive the critical effect for Daptomycin, sometimes at doses well below those causing general toxicity. The assessment therefore looks at the mechanism of action, the lowest doses associated with pharmacological effects and the target population, and uses this information when selecting the point of departure and the adjustment factors.

An OEL is derived by reviewing the toxicological and occupational health evidence, identifying the critical effect, and applying a recognized assessment methodology. The final value should come with a documented rationale, clearly stated units, and the exposure duration it applies to, so it can be used confidently in workplace risk assessment.

An OEB places Daptomycin in a hazard category using a defined banding framework and the available toxicological evidence. Criteria and numerical ranges differ between frameworks, so the report should identify the system used. The band then guides the level of containment and handling controls suited to the compound.

Not necessarily. A PDE or ADE is derived for a defined route of exposure, often oral for carryover into the next product. Extrapolating to inhalation or dermal exposure needs scientific justification, so the report should state the route, scope, and assumptions behind the value.

The assessment of Daptomycin can draw on non-clinical toxicology studies, clinical trial data, post-marketing safety information and knowledge of the mechanism of action. Information on bioavailability by different routes may also be relevant. Each source is weighed for quality and relevance, and gaps are addressed with documented, scientifically justified assumptions.

Yes, health-based limits can be relevant for peptide and protein products such as Daptomycin. A PDE supports cross-contamination control in shared facilities, while an OEL or OEB helps protect workers handling the material. The assessment takes into account how the molecule acts, how it is absorbed and how it may be degraded, which can differ from small molecules.

Masuu Global follows a scientifically justified, risk-based approach aligned with internationally recognized guidance accepted by regulators, including the EMA guideline on health-based exposure limits, PIC/S guidance on shared facilities and contamination control, ICH Q9 quality risk management, and ICH M7 where applicable.

Use the Request Your Assessment option on this page and add Daptomycin to your inquiry list. The Masuu Global team will follow up with full documentation, pricing, and licensing terms. Mention your intended use and market so the scope of the report can be confirmed.

Book a Demo